VBIV VBI Vaccines Dashboard

VBI Vaccines Inc. is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, which is approved for use and commercially available in Israel under the name Sci-B-Vac® and completed its Phase 3 program in the U.S., Europe, and Canada in 2020; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI's enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI's lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Company profile

Ticker

VBIV

Exchange

NASDAQ

Website

www.vbivaccines.com

CEO

Jeffrey R. Baxter

Incorporated

British Columbia, Canada

Location

Massachusetts

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

LEVON RESOURCES LTD, LEVON RESOURCES LTD., SciVac Therapeutics Inc.

SEC CIK

0000764195

Corporate docs

Articles of Incorporation & Bylaws

VBIV stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

VBI Vaccines Announces Data Form Phase 1b/2a Study Of Its Hepatitis B Immunotherapeutic Candidate Showing Robust HBV Specific T Cell Responses In ≥ 50% Of Evaluable Patients

12 Apr 21

Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179)

CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants

10 Mar 21

The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV)

Coalition for Epidemic Preparedness Innovations To Provide Up To $33M To Support Advancement OF VBI Vaccines' VBI-2905 Vaccine Candidate

10 Mar 21

Up to $33m of funding will support development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern. Phase 1 clinical study of VBI's eVLP vaccine

VBI Vaccines Moves Forward With Prophylactic COVID-19 Vaccine Study

9 Mar 21

VBI Vaccines Initiates Enrollment In Adaptive Phase 1/2 Study Of Prophylactic COVID-19 Vaccine Candidate, VBI-2902

9 Mar 21

Press releases

Pro users get this 30m faster

VBI Vaccines Announces Phase 1b/2a Data and Progress of Hepatitis B Immunotherapeutic Candidate

12 Apr 21

Data from Phase 1b/2a study in chronic HBV patients show robust HBV specific T cell responses in ≥ 50% of evaluable patients across all study arms of VBI-2601 (BRII-179) VBI-2601 (BRII-179) was well-tolerated with no

CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants

10 Mar 21

Up to $33m of funding will support development of VBI's enveloped virus-like particle (eVLP) vaccine candidates against COVID-19 variants of concern. Phase 1 clinical study of VBI's eVLP vaccine candidate, VBI-2905,

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

2 Mar 21

18 Apr 21

31 Dec 21

Financial summary

Financial statements Chart VBIV financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	93.83M	93.83M	93.83M	93.83M	93.83M	93.83M
Cash burn (monthly)	444.33K	(positive/no burn)	5.12M	3.94M	5.5M	3.92M
Cash used (since last report)	1.61M	n/a	18.52M	14.25M	19.89M	14.18M
Cash remaining	92.22M	n/a	75.3M	79.57M	73.94M	79.64M
Runway (months of cash)	207.5	n/a	14.7	20.2	13.4	20.3

Beta Read what these cash burn values mean

Recent insider trades

VBIV insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 21	Baxter Jeff	Option (Right to Buy Common Shares) Common Shares	Grant	Aquire A	No	No	3.15	1,000,000	3.15M	1,000,000
27 Jan 21	Steven Gillis	Option (Right to Buy Common Shares) Common Shares	Grant	Aquire A	No	No	3.15	100,000	315K	100,000
27 Jan 21	Anderson David Evander	Option (Right to Buy Common Shares) Common Shares	Grant	Aquire A	No	No	3.15	500,000	1.58M	500,000
27 Jan 21	McNulty Christopher	Option (Right to Buy Common Shares) Common Shares	Grant	Aquire A	No	No	3.15	500,000	1.58M	500,000
27 Jan 21	Joanne Cordeiro	Option (Right to Buy Common Shares) Common Shares	Grant	Aquire A	No	No	3.15	75,000	236.25K	75,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

VBIV institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

47.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	123	113	+8.8%
Opened positions	34	25	+36.0%
Closed positions	24	13	+84.6%
Increased positions	48	39	+23.1%
Reduced positions	25	39	-35.9%

13F shares	Current	Prev Q	Change
Total value	431.02M	492.59M	-12.5%
Total shares	121.55M	126.18M	-3.7%
Total puts	934.9K	1.32M	-29.0%
Total calls	531.4K	808.4K	-34.3%
Total put/call ratio	1.8	1.6	+8.0%

Largest owners	Shares	Value	Change
Perceptive Advisors	55.04M	$151.37M	0.0%
STT State Street	22.29M	$61.31M	+20.1%
BLK Blackrock	13.18M	$36.23M	+7.8%
Vanguard	5.51M	$15.14M	+8.5%
Geode Capital Management	2.96M	$8.15M	+4.9%
NTRS Northern Trust	2.1M	$5.77M	+2.7%
Cambridge Investment Research Advisors	1.65M	$4.52M	-10.4%
GAM General American Investors	1.64M	$4.5M	+63.5%
Charles Schwab Investment Management	1.4M	$3.86M	+4.7%
Susquehanna International	1.29M	$3.56M	+31.3%

Largest transactions	Shares	Bought/sold	Change
Viking Global Investors	0	-8.8M	EXIT
STT State Street	22.29M	+3.73M	+20.1%
Two Sigma Investments	0	-1.92M	EXIT
Millennium Management	0	-1.88M	EXIT
tru Independence	1.01M	+1.01M	NEW
BLK Blackrock	13.18M	+948.86K	+7.8%
GAM General American Investors	1.64M	+635.19K	+63.5%
Commonwealth Equity Services	571.12K	+571.12K	NEW
Two Sigma Advisers	22.5K	-462.5K	-95.4%
Vanguard	5.51M	+433.16K	+8.5%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Dynavax Technologies • Hookipa Pharma

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abrogating, accuracy, Africa, AgreementSM, alia, amalgamation, Ankura, Area, AstraZeneca, ATM, baseline, BCF, BCPIA, Biden, binding, biodefense, Biomedical, BioNTech, Braga, brand, Britain, broaden, BV, CDMO, circulation, client, collateral, coping, copy, COVID, CureVac, Damian, deadly, dedicated, deep, deployment, difficulty, disputed, dissipate, EC, ECDRP, EEA, encourage, explanatory, feature, footprint, formidable, Gag, globe, Great, hamper, hearing, hundred, HVB, Iceland, ideal, IIa, importantly, inadvertent, infiltration, innate, InVentiv, IRAP, Ireland, isolated, Johnson, leadership, lesser, Liechstenstein, load, longevity, Majesty, Medicago, MHRA, Minister, Minster, morphologically, mutated, necessitated, Northern, Norway, Novavax, nucleotide, obesity, obligor, opponent, Pacific, pandemic, paragraph, particulate, PDUFA, precautionary, Preceptive, prefusion, prepaid, prepayment, prime, prioritize, procurement, PRs, pseudoprogression, pursuit, Queen, reactive, readily, reallocate, receptor, recession, rectification, redacted, refinanced, relaxed, remediation, reperfoming, reperforming, repetitive, Resilience, resurgence, RNA, route, running, satisfactory, SE, shelf, shrinkage, SIF, signatory, skill, SNO, Sorbonne, specialist, Speed, spike, spontaneously, spread, subsided, suggesting, symptomatic, Therapure, today, topline, transmissibility, transmit, Trust, Twinrix, UK, unadjuvanted, Universit, Universite, unprecedented, unrealized, unreasonably, unredacted, unregistered, Valneva, variant, verified, vouching, Warp, worsening

Removed: Adam, aseptic, billion, brain, Buckley, Canaccord, cap, capped, comparative, content, deciding, display, dissolved, distribute, epithelial, exemption, filling, Florida, Genuity, geometric, immunologic, index, induced, inInternal, leveraging, LIBOR, manager, membrane, Miami, obliging, OPKO, outbound, package, percent, periodically, pool, preclinical, presidential, purification, reclassified, recommended, remeasured, reorganization, repurchased, resigned, secondary, statuary, synthetically, ticker, traditional, upstream, USA

From filing 10-K 2020 FY